PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study to Compare Different Preparations of Sisunatovir in Healthy Adult Participants.
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 25
- Registration Number
- NCT05994963
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Study to Learn How the Study Medicine Called Sisunatovir is Tolerated and Acts in the Bodies of Chinese Healthy Adults.
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT05987072
- Locations
- 🇨🇳
Huashan Hospital, Shanghai, Shanghai, China
🇨🇳Huashan Hospital, Fudan University, Shanghai, Shanghai, China
🇨🇳Huashan Hospital Fudan University, Shanghai, Shanghai, China
A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1238
- Registration Number
- NCT05989048
- Locations
- 🇨🇳
Chang Gung Medical Foundation-Linkou Branch, Taoyuan, Taiwan
🇨🇳Liaocheng people's Hospital, Liaocheng, Shandong, China
🇨🇳The Second People's hospital of Hefei, Hefei, Anhui, China
Voxelotor CYP and Transporter Cocktail Interaction Study
- Conditions
- Sickle Cell Disease
- Interventions
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 44
- Registration Number
- NCT05981365
- Locations
- 🇺🇸
ICON Early Phase Services, LLC, San Antonio, Texas, United States
A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2733
- Registration Number
- NCT05968599
- Locations
- 🇺🇸
Pfizer Inc, New York, New York, United States
A Study to Learn About the Study Medicine Called Zavegepant in Healthy Chinese Adult Participants
- First Posted Date
- 2023-07-25
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 13
- Registration Number
- NCT05960032
- Locations
- 🇨🇳
Huashan Hospital,Fudan University, Shanghai, Shanghai, China
A Study to Evaluate the Study Medication (Etrasimod) When Mixed With Food in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- Drug: Estraimod Immediate Release (IR)
- First Posted Date
- 2023-07-21
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT05956002
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings
- Conditions
- Metastatic Melanoma
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 275
- Registration Number
- NCT05954546
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
A Study to Compare Zavegepant Concentration Using Samples Collected From the Vein Versus Patient-Centric Microsampling
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT05948085
- Locations
- 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States
A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 514
- Registration Number
- NCT05932290
- Locations
- 🇺🇸
Pfizer, New York, New York, United States